Notch
Notch develops stem cell–derived T cell immunotherapies for cancer treatment.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Therapeutics, Life Sciences
Is this your organization? Claim it
Recent coverage
Front-page news, podcasts and videos about Notch
Notch Therapeutics raises $85M Series A (total $91M) to fund stem cell–derived T cell therapies and open Seattle lab
Notch Therapeutics raised an $85 million Series A, bringing total funding to $91 million, to advance stem cell–derived T cell immunotherapies and expand with a new Seattle research lab. The 2018-founded biotech plans to grow from 35 to about 100 employees by end of 2022 and is collaborating with Allogene Therapeutics on treatments for blood cancers.
Questions about Notch
What is Notch?
Notch is a startup that develops stem cell–derived T cell immunotherapies for cancer treatment and is based in Seattle.
What has Notch been in the news for?
GeekWire reported in February 2021 on Notch’s plans to develop stem cell–derived T cell therapies and open a Seattle lab.
Where is Notch based?
Notch is based in Seattle.